Clinical Trials Logo

Emphysema clinical trials

View clinical trials related to Emphysema.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06000696 Enrolling by invitation - COPD Clinical Trials

Healthy at Home Pilot

Start date: September 9, 2022
Phase:
Study type: Observational [Patient Registry]

The objective is to conduct a pilot-feasibility trial of the "Healthy at Home" program, a multimodal intervention aimed at preventing acute care needs among COPD patients. The program will feature a digital platform and virtual pulmonary rehabilitation to facilitate complex care management of UMass Memorial Health Patients

NCT ID: NCT04930289 Enrolling by invitation - Cystic Fibrosis Clinical Trials

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

GUARDIANLUNG
Start date: October 15, 2021
Phase:
Study type: Observational [Patient Registry]

The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as retrospective standard of care patients

NCT ID: NCT02796937 Enrolling by invitation - Clinical trials for Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

SPARTA-OLE
Start date: July 2016
Phase: Phase 3
Study type: Interventional

This is a 2-year open-label, multicenter extension of the double-blind, placebo-controlled GTi1201 study. The purpose of this study is to obtain an additional 2 years of safety data for intravenously administered Alpha1-MP 60 mg/kg/week in subjects with alpha1-antitrypsin deficiency (AATD).

NCT ID: NCT01466712 Enrolling by invitation - COPD Clinical Trials

Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function

Start date: November 2011
Phase: Phase 4
Study type: Interventional

Inuvair® is a novel fixed combination product used in the treatment of asthma and under clinical development for the treatment of COPD. Thanks to the extrafine particle size, it is able to target the whole bronchial tree, including the small airways and hence, is expected to act in these airways and it may thus be beneficial in COPD in that sense. In COPD, its action on the small airways is not directly demonstrated thus far. By way of contrast, dear evidence is present that treatment with bronchodilators alone does not beneficially alter small airway function. The study hypothesis states that the effects of inhaled corticosteroids or ICS/LABA combinations on small airway is present and can be objectivated.